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Abstract
Background: The aims of the study are 1) to assess antiarrhythmic prophylaxis efficacy dur-
ing the first 2 months after radiofrequency ablation (ARF) due to AF; 2) to define risk factors 
for early AF recurrence (EAFR) after ARF; 3) to determine the long-term follow-up results and 
risk factors for late AF recurrence (LAFR).
Methods: A total number of 210 consecutive patients who had undergone ARF due to AF 
were analyzed. Patients were randomized into three groups: Group 1 (G1), without any anti-
arrhythmic drug (AAD); Group 2 (G2), with amiodarone or sotalol; Group 3 (G3), with last 
ineffective AAD. The study was designed to analyze two periods: short-term observation, the 
first 2 months after ARF; and at least 2 years of long-term follow-up.
Results: After 2 months, clinical data were collected from 171 patients (123 males, mean age 
of 50.3 years; persistent AF in 19.8%; lone AF in 36.6%). Sinus rhythm (SR) was maintained 
in 84 (49.1%) patients; 35 (20.4%) patients presented with a single episode of AF, 39 (23%) 
patients experienced a reduction in number of AF episodes, and 13 (7.5%) patients showed no 
improvement. No predisposing factor for early recurrence was found. After a mean follow-up 
of 55 months, clinical data were collected in 137 patients, of which 47 (34%) maintained SR. 
Those more likely to sustain SR were: males (82.9% vs. 62.2%; p = 0.018), younger patients 
(44.8 ± 12.7 vs. 52.5 ± 9.9; p = 0.0001), patients with smaller left atrium diameter (4.05 ±  
± 0.49 cm vs. 4.25 ± 0.51 cm; p = 0.04), and those without any AF recurrence during the first 
2 months after ARF (78.7% vs. 35.6%; p < 0.0001). In the multivariable analysis, the inde-
pendent risk factors for LAFR were hypertension (p < 0.001) and persistent AF (p = 0.014).
Conclusions: Antiarrhythmic prophylaxis does not affect the number of AF recurrences 
during the first 2 months after ablation. SR maintenance during a blanking period after AF 
ablation is a positive prognostic factor in long-term follow-up. Persistent AF and hypertension 
are independent risk factors for late AF recurrence after pulmonary vein isolation. (Cardiol J 
2014; 21, 4: 384–391)
Key words: pulmonary vein isolation, atrial fibrillation, early AF recurrence, 
late AF recurrence
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Introduction
Atrial fibrillation (AF) is the most common 
supraventricular tachyarrhythmia and is respon-
sible for one third of all hospital admissions due 
to arrhythmia. The incidence of AF is 1–2% of the 
total population and increases with the age [1, 2] 
up to 8% in the population over 80 years [3].
Radiofrequency ablation with pulmonary vein 
isolation (PVI) is an accepted method for treatment of 
AF [4]. Despite the sophisticated technology involved 
in AF ablation therapy, however, AF recurrence may 
be observed either in the early period after PVI or 
during long-term follow-up. In some patients, tem-
poral exacerbation of AF is observed during the early 
period after PVI. Furthermore, it is not clearly defined 
when the early periods ends and when the late period 
starts. Previously, AF recurrences during the first 
weeks after PVI were treated as a non-significant 
factor, but nowadays they are regarded to have an 
impact on long-term PVI failure [5–7].
Antiarrhythmic prophylaxis with limited ef-
ficacy may result in adverse effects [8–10]. The 
role of early AF recurrence is unclear.
This study has three main aims: 1) to find 
the risk factors for early and late recurrence of 
AF after PVI, 2) to assess the importance of early 
AF recurrence, and 3) to check the usefulness of 
antiarrhythmic prophylaxis during the early period 
after PVI.
Methods
The study was conducted in prospective ran-
domized mode. A total number of 210 consecutive 
patients who had undergone PVI due to AF were 
analyzed (2003–2007). In all patients, reversible 
causes of AF were excluded, as was pre-procedural 
left atrial appendage thrombus. The inclusion 
criteria were: 1) first PVI due to AF; 2) age above 
18 years; and 3) sinus rhythm (SR) during the 
first 24 h after PVI. The exclusion criteria were: 
1) reversible cause of AF; 2) bradycardia of 50 bpm 
or less, atrioventricular or intraventricular blocks; 
3) contraindications to antiarrhythmic agents used 
during study (in case of contraindications to ami-
odarone, sotalol was used); and 4) PVI procedure 
with heart tamponade complication.
The study group was randomly divided into 
three groups:
 — Group 1: patients without any antiarrhythmic 
agent (G1);
 — Group 2: patients receiving amiodarone (or 
sotalol in case of amiodarone contraindica-
tions) (G2); and
 — Group 3: patients with last ineffective an-
tiarrhythmic agent used before PVI (G3).
The above therapy scheme was continued for 
2 months after PVI.
At discharge, all patients were planned for at 
least two 24-h Holter electrocardiography (ECG) 
registration, followed by a control visit after the 
first and second months after PVI. They were also 
asked to provide symptoms registration during 
the first 2 months after PVI and to complete ECG 
documentation in case of any arrhythmia symptoms 
occurrence. After a minimum period of 2 years after 
PVI, the patients were called for a follow-up visit, 
or medical data were obtained through a telephone 
call. Every episode of AF lasting 30 s or more was 
classified as AF recurrence (Fig. 1).
The AF recurrence rate was assessed after an 
analysis of all available rhythm recordings: 24-h 
Holter monitoring at 30 and 60 days after PVI and 
every ECG registration made on occurrence of 
symptoms suggesting arrhythmia.
Due to different protocols on result description 
among different centers, the medical data gathered 
during follow-up were inconsistent. To make them 
comparable, the results were divided into groups:
 — patients with successful PVI:
• patients without AF recurrence;
• patients with a single AF episode;
 — patients with unsuccessful PVI:
• patients with subjective improvement 
but insignificant reduction in number of 
AF episodes;
• patients without change in AF intensity.
Figure 1. Study flowchart. PVI — pulmonary vein isola-
tion; AF — atrial fibrillation; A/S — amiodarone/sotalol; 
AAD — antiarrhythmic drug; SR — sinus rhythm.
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During short-term observation, two groups of 
patients, those without AF recurrence and those 
with a single episode of AF, were treated as suc-
cessful PVI procedures, whereas the groups with 
a reduction in severity of AF and without any 
change were regarded as procedural failures. Ana-
lysis was performed separately in the subgroups 
(no AF, single AF episode, unsuccessful PVI) and 
the cumulative successful/unsuccessful groups.
During long-term observation, there were only 
two groups considered: patients with SR and those 
with documented recurrence of AF. Clinically impor-
tant, AF recurrence was defined as any documented, 
ECG-recorded episode of AF lasting at least 30 s.
The study was approved by the local bioethi-
cal committee and all patients gave their informed 
consent.
Antiarrhythmic treatment
Antiarrhythmic drugs (AAD) were withdrawn 
7 days before the procedure in case of amiodarone, 
beta-blocker, propafenone, and sotalol use, with 
gradual dosage reduction stopped 2 days before 
PVI. Antiarrhythmic agents were initiated during 
the first 24 h after the procedure.
Pulmonary vein isolation
In all cases, segmental PVI was done with 
a 4 mm-tip not irrigated conventional radiofre-
quency catheter (Marinr, Medtronic) with 30–35 W 
power and a 50oC cutoff (RF generator Atakr II, 
Medtronic). Pulmonary veins were mapped with 
a 10-pole circular diagnostic catheter with varia-
ble diameter (Lasso 2515, Biosense-Webster). 
LocaLisa system (Medtronic) was used as an ad-
ditional tool to fluoroscopy for catheter position 
control during energy delivery.
Study end points
The end points of the study are: SR main-
tenance during the first 2 months after PVI, 
a proarrhythmic event during this period, and SR 
maintenance during at least 2 years of follow-up.
Statistical analysis
Continuous data were presented as mean 
values with standard deviation or as mean values 
with media. Differences among continuous data 
were evaluated by Student’s t-test. Categorical 
data were presented as numbers and percentages, 
and compared with Pearson’s c2 test. The relation-
ship among continuous data was tested with the 
Spearman rank correlation coefficient. Differences 
among the three groups were tested with one-way 
ANOVA. Multivariate analysis was performed with 
the linear regression method. The statistical sig-
nificance level was p < 0.05. Data were analyzed 
with the STATISTICA (Statsoft Poland) software.
Results
Two months after ablation
Table 1 shows the clinical and demographic 
data of the patients. The study population consisted 
of 180 patients (mean age of 50.2 ± 11.2 years, 
123 males). In 36 patients, a persistent form of AF 
was recognized.
A total number of 180 patients were rando-
mized into one of the following three groups:
 — Group 1 (G1): without antiarrhythmic agent 
(60 patients);
 — Group 2 (G2): with amiodarone (30 patients) 
or sotalol (32 patients);
 — Group 3 (G3): with last ineffective anti-
arrhythmic agent (58 patients).
Two patients randomized to G3 received so-
talol before PVI; therefore, they were moved to 
G2. Reliable data after 2 months were available 
in 171 patients (G1: 57 patients; G2: 59 patients; 
G3: 55 patients). Table 2 presents the groups’ 
characteristics.
Occurrence of end points
Early period after PVI. During first 2 months 
after PVI, 84 (49.1%) patients were free of any 
AF recurrence, 35 (20.4%) experienced a single 
episode of AF, 39 (23%) showed an insignificant 
reduction in AF burden, and 13 (7.5%) presented 
no change in clinical status.
Table 1. Clinical and demographic characteristic 
of the study population. 
Age [years] 50.2 ± 11.2
Male 123 (68.3%)
AF duration [months] (med) 79.2 (60)
Persistent AF 36 (20%)
AF episodes [no/month] (med) 12.8 (8)
LA diameter [cm] (med) 4.2 (4.2)
Coronary artery disease 18 (10%)
Hypertension 83 (46.1%)
Diabetes mellitus 11 (6.1%)
Chronic heart failure 2 (1.1%)
Dyslipidemia 31 (17.2%)
Antiarrhythmic drugs 5 ± 2
Continuous variables presented as mean values and standard  
deviation (SD) or median (med). Categorical variables presented as 
numbers and percentages; AF — atrial fibrillation; LA — left atrium
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Table 3 presents the frequency of particular 
end points. In Group 2, there was a higher number 
of persistent AF patients than in the other groups 
(G1 vs. G2 vs. G3: 14% vs. 28.8% vs. 16.3%; p = 0.08).
In G1, 31 (54.3%) patients maintained SR, and 
9 (15.7%) patients experienced a single episode of 
AF. In 40 (70%) patients, the PVI procedure was 
successful during short-term observation (sum-
mary of SR and single AF episode). In the other 
groups, the results presented were: G2: 28 (47.5%) 
patients with SR; 9 (15.2%) patients with single AF 
episode — summary successful PVI in 37 (62.7%) 
patients, G3, respectively: 25 (45.5%) patients; 
17 (30.9%) patients — summary 42 (76.4%) patients, 
which was statistically insignificant. No indepen-
dent risk factor for early recurrence of AF was 
found in the multivariate analysis. More than 90% 
of all AF recurrences occurred during the first 
30 days of observation (22 ± 13.5).
To check for the impact of any antiarrhythmic 
treatment, the results obtained during the first 
2 months after PVI were analyzed for frequency of 
AF recurrences in two subgroups: G1 and cumula-
tive G2 and G3 (Table 4).
Long-term results. During the mean 55-month 
observation period, reliable data were availa-
ble in 137 (80.1%) patients. During this time, 
47 patients maintained SR, equivalent to 34% of 
the study group. Patients with repetitive PVI were 
classified under AF recurrence, and the final PVI 
Table 3. End point occurrence in the study group during 2 months of observation.
G1 (n = 57) G2 (n = 59) G3 (n = 55) Total (n = 171) P
AF episodes
Without AF 31 (54.3%) 28 (47.5%) 25 (45.5%) 84 (49.1%) 0.34
Single AF episode 9 (15.7%) 9 (15.2%) 17 (30.9%) 35 (20.5%) 0.09
Reduction in AF episodes 13 (23%) 17 (28.8%) 9 (16.4%) 39 (23%) 0.74
Without change 4 (7%) 5 (8.5%) 4 (7.2%) 13 (7.6%) 0.58
Proarrhythmia
QT prolongation 0 2 (3.3%) 0 2 (1.1%)
Atypical atrial flutter 0 2 (3.3%) 1 (1.8%) 3 (1.7%)
AF exacerbation 1 (1.7%) 0 0 1 (0.5%)
Total proarrhythmia 1 (1.7%) 4 (6.6%) 1 (1.8%) 6 (3.3%)
P value for G1 vs. G2 vs. G3; abbreviations as in Table 2
Table 2. Characteristics of the study group with short-term follow-up. 
G1 (n = 57) G2 (n = 59) G3 (n = 55) Total (n = 171) P
Age [years] 47.6 ± 13 50.8 ± 10 52.5 ± 11 50.3 ± 11.2 0.18
Body mass index [kg/m2] 27.7 ± 4.7 28.5 ± 5.1 28.7 ± 4.6 28.6 ± 4.9 0.78
LA diameter [cm] 4.1 ± 0.4 4.3 ± 0.6 4.2 ± 0.6 4.2 ± 0.6 0.2
Male 41 (71.9%) 42 (71%) 35 (63.5%) 123 (68.3%) 0.58
AF duration [months] (med) 76 (48) 80.24 (60) 83.3 (60) 79.6 (60) 0.96
Persistent AF 8 (14%) 17 (28.8%) 9 (16.3%) 34 (19.8%) 0.07
AF episodes [month] (med) 11.5 (5.5) 15.5 (10) 10.7 (8) 12.4 (8.5) 0.2
Coronary artery disease 5 (8.8%) 7 (12%) 6 (10.9%) 18 (11%) 0.86
Hypertension 22 (39%) 29 (49%) 27 (49.1%) 78 (46%) 0.5
Diabetes 2 (3.5%) 4 (6.8%) 4 (7.2%) 10 (5.8%) 0.53
Chronic heart failure 1 (1.8%) 1 (1.6%) 0 (0%) 2 (1.2%) 0.62
Mitral regurgitation 1 (1.8%) 3 (5.1%) 1 (1.8%) 5 (2.9%) 0.24
Dyslipidemia 8 (12%) 11 (19%) 10 (18.2%) 28 (16%) 0.82
ACEI 20 (35%) 26 (44.1) 25 (45.5%) 71 (42%) 0.56
Beta-blockers 0 0 13 (23%) 13 (7.6%)
G1 — patients without antiarrhythmic agent; G2 — patients with amiodarone/sotalol; G3 — patients with last ineffective antiarrhythmic agent; 
ACEI — angiotensin-converting enzyme inhibitor; AF — atrial fibrillation; LA — left atrial
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results were not included in further analysis — 
some of repetitive PVI were performed in different 
center.
There were statistically significant differences 
among groups with SR and AF recurrence: patients 
with successful PVI were younger (44.8 ± 12.7 vs. 
52.5 ± 9.9 years; p = 0.0001), had no hypertension 
(34% vs. 53.3%; OR 2.2; 95% CI 1.06–4.6; 
p = 0.04), and had a smaller left atrial diameter 
(4.05 ± 0.49 cm vs. 4.25 ± 0.55 cm; p = 0.04) 
(Table 5).
The findings obtained from the mean 55-month 
observation period showed that the antiarrhythmic 
strategy during the first 2 months of follow-up does 
not impact long-term results. Among patients with 
SR during the first 2 months after PVI, 78.7% had 
no AF recurrence during long-term follow-up, 
compared with 35.6% in the early recurrence group 
(p < 0.0001; Table 6). In summary, the long-term 
success rate in patients with SR during the first 
2 months after PVI was 53.6%, whereas in patients 
with even one single early recurrence of AF, the 
percentage dropped to 26.3% (Fig. 2).
Hypertension and persistent AF were inde-
pendent risk factors for AF recurrence in long-
term observation: 0.618; 95% CI 0.395–0.842; 
p < 0.001 and 0.48; 95% CI 0.103–0.857; p = 0.014, 
respectively.
Table 4. Cumulative incidence of atrial fibrillation (AF) in patients without antiarrhythmic treatment and 
with any antiarrhythmic agent. 
Without AAD (n = 57) On AAD (n = 114) P
Successful PVI (without AF + single episode AF) 40 (70.2%) 79 (69.3%) 0.52
Without AF 31 (54.4%) 53 (46.5%) 0.21
AAD — antiarrhythmic drug; PVI — pulmonary vein isolation
Table 5. Characteristics of the study group in long-term observation. 
Patients with SR Patients with AF P
Male gender 39 (82.9%) 56 (62.2%) 0.018
Age 44.8 ± 12.7 52.5 ± 9.9 0.0001
Time to recurrence 176.3 ± 247.7 249.7 ± 362.8 0.58
Left atrial diameter [cm] 4.05 ± 0.49 4.25 ± 0.51 0.04
Body mass index [kg/m2] 28.9 ± 4.7 28.1 ± 5.05 0.4
AF duration [months] 79.95 ± 73.83 79.73 ± 55 0.98
Persistent AF 7 (14.8%) 20 (22.2%) 0.21
AF episodes/month 14.5 ± 14.3 10.9 ± 10.4 0.18
Coronary artery disease 5 (10.6%) 11 ± 12.2 0.52
Hypertension 16 (34%) 48 (53.3%) 0.04
Diabetes mellitus 4 (8.5%) 5 (5.5%) 0.38
Dyslipidemia 6 (12.7%) 18 (20%) 0.25
Categorical variables presented as sums and percentages; continuous variables presented as averages and standard deviation (SD). AF dura-
tion, persistent AF and number of AF episodes/month — pre-ablation data; AF — atrial fibrillation; SR — sinus rhythm
Table 6. The influence of first 2 months results after pulmonary vein isolation on long-term results.
Results after 2 months Sinus rhythm AF recurrence Long-term success rate P
Without AF 37 (78.7%) 32 (35.6%) 53.6% < 0.0001
Single AF episode 5 (10.6%) 14 (15.5%) 26.3% 0.3
Reduction of AF 5 (10.6%) 32 (35.5%) 15.6% 0.0012
No change 0 (0%) 12 (13.3%) 0% 0.005
AF — atrial fibrillation
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Discussion
This study aimed to verify the hypothesis that 
AAD impact the results of PVI during the early 
period. Long-term verification, although difficult, 
was also performed. Our single-center study group 
consisted of consecutive patients qualified for PVI, 
which makes the whole group more representative 
of the general population.
Influence of post-ablation antiarrhythmic 
prophylaxis on AF recurrence frequency
This study found no association between an-
tiarrhythmic strategy and PVI results during the 
early period after radiofrequency ablation, which 
is opposite to previously published data [11]. In 
the 5A study Antiarrhythmics After Ablation of 
Atrial Fibrillation, Roux at al. [11] assessed anti-
arrhythmic prophylaxis during the first 6 months 
after PVI. A total number of 110 patients were 
randomized into two groups: those using AAD and 
those without any prophylaxis. The clinical char-
acteristics of the patients presented in this study 
were similar to those in the 5A study population; 
however, persistent AF patients were excluded 
in the latter. In the 5A study, AAD resulted in 
a significant reduction in number of AF recurren-
ces, hospital admissions, cardioversions, and drug 
change due to symptomatic atrial arrhythmias: 19% 
in the AAD group vs. 42% in those without AAD 
(p = 0.005). Why do these two similar studies show 
opposite results? The answer may lie in the study 
methodology and the assessment criteria for the 
end result. First of all, the study population was 
different: in our study, both paroxysmal and per-
sistent patients were included, but prior PVI was 
a criterion for exclusion. Persistent AF patients 
were distributed among three groups evenly. Thus, 
the reason may be the difference in the definition 
of AF recurrence. In both studies, every atrial 
tachyarrhythmia was treated as AF recurrence, 
but in the 5A study, the time criterion was different 
from that recommended in the guidelines. That is, 
the 5A study specified that arrhythmia should last 
at least 24 h or that the symptoms should lead to 
earlier cardioversion; according to the guidelines, 
this time criterion should be 30 s. The definition 
of recurrence in the 5A study may lead to un-
derestimation of the real number of arrhythmia 
episodes in a study group. Such a definition seems 
controversial, especially in the continuation of the 
5A study where, during 6 months of observation, 
AF recurrence was defined as lasting 60 s or more 
[12]. In our study, the AAD group was divided to 
check the hypothesis that AAD that is ineffective 
before ablation may be successful in AF preven-
tion after PVI. The results presented in this study 
showed that this hypothesis is false. To compare 
the results of both studies, a separate analysis was 
made on patients without AAD vs. those receiving 
any AAD. There were no significant differences in 
recurrence rate in both groups.
AF recurrence risk factors during  
the early period after PVI
This study found no risk factor for early AF re-
currence (EAFR) after PVI. Other studies obtained 
similar results, even with the definition of early 
period extended to 3 months and ECG registration 
with loop recorders [13].
More than 90% of all EAFR occurred within 
the first 30 days after PVI (mean of 22 days). These 
data are also consistent with those previously 
published: 54% EAFR during the first 2 weeks 
after PVI, 38% occurring during the next 2 weeks, 
and at least one clinically significant AF episode 
in 65% of patients [13]. In case of any symptoms 
suggesting arrhythmia recurrence, a standard ECG 
was performed. Hindricks et al. [14] screened 
patients before and after PVI. They reported that 
before PVI, only symptomatic AF episodes oc-
curred in 38% of patients, both symptomatic and 
asymptomatic ones in 57%, and only asymptomatic 
arrhythmia in 5%. During 6 months of observation 
after PVI, only asymptomatic AF was registered in 
37% of patients. Asymptomatic AF recurrences are 
not only a matter of success assessment. In case of 
highly symptomatic AF before PVI, patients with 
asymptomatic arrhythmia after ablation consider 
Figure 2. Comparison between long-term and short-term 
observation results; SR — sinus rhythm; AF — atrial 
fibrillation; Early period results: 1 — no AF; 2 — single 
AF episode; 3 — reduction of AF reccurences; 4 — no 
change.
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themselves cured. Improvement of quality of life 
is one of the therapeutic goals, but asymptomatic 
AF episodes imply a thromboembolic risk despite 
patients’ better clinical status.
Late AF recurrence risk factors
During the mean 55-month observation pe-
riod, only 34% of patients maintained SR after 
a single PVI procedure. The observation period in 
different publications ranges from 6 months to 
6 years. Although single and repetitive procedures 
were included in these studies, the common con-
clusion is that long-term results are less optimistic 
than short-term ones. One study reported a 6-year 
success rate of 23% after a single procedure and 
of 39% after repetitive ablation.
In this study, SR maintenance during the 
first 2 months decreased the late AF recurrence 
rate significantly independently from prior anti-
arrhythmic strategy: 78.7% of patients without 
late AF recurrence maintained SR during the 
first 2 months of observation (p < 0.0001), and 
the long-term success rate in this subgroup was 
53.6%. Even a single AF episode during the first 
2 months reduced this result twice. The available 
publications during the patient enrolment phase 
showed no association between early AF recur-
rence and long-term results [7]. This is opposite 
to the data presented by Arya et al. [16] and Cai 
et al. [6]. In the first study, the independent risk 
factors for late AF recurrence were: early AF re-
currence (HR 4.3; 95% CI 2.0–9.1; p = 0.0001), left 
atrial diameter ≥ 50 mm (HR 4.6; 95% CI 2.9–9.1; 
p = 0.0001), and hypertension (HR 3.3; 95% CI 
1.4–7.5; p = 0.003); in the second, the risk factors 
were overweight (HR 4.71; 95% CI 1.71–12.98; 
p = 0.003), metabolic syndrome (HR 4.41; 95% CI 
1.56–12.46; p = 0.005), and early AF recurrence 
(HR 3.18; 95% CI 1.07–9.44; p = 0.037). In this 
study, we found no connection between body mass 
index and increased number of AF recurrence.
In the Bordeaux group, the 5-year follow-up 
was based on 24-h Holter registration and standard 
ECG in case of symptoms suggesting arrhythmia 
recurrence with duration of 30 s of more as a diag-
nostic criterion for a clinically significant episode 
[15]. In the success rate analysis, a time-dependent 
reduction in freedom from AF was observed. After 
1, 2, and 5 years of observation, SR was maintained 
in 40%, 37%, and 29% of patients, respectively. 
This study group included long-lasting persistent 
AF patients. This form of arrhythmia was the only 
independent risk factor for late AF recurrence.
Limitations of the study
Similar to other studies, the SR documenta-
tion method is the most important limitation of 
this work. The use of 24-h ECG registration and 
standard ECG in case of symptoms suggesting 
arrhythmia recurrence may lead to underestima-
tion of the real recurrence rate. The study group 
consisted of patients from different regions of the 
country; thus, the results of the Holter ECG moni-
toring were presented in different manners. To 
make them comparable, categories of results were 
used instead of objective arrhythmia counts. Dif-
ferent types of AF may have influence the results 
although no long lasting persistent AF patients 
were enrolled.
Conclusions
Antiarrhythmic drugs do not reduce the in-
cidence of early AF recurrence after pulmonary 
vein isolation. SR maintenance during the blanking 
period seems to be a strong positive predictor of 
long-term success after ablation. Hypertension and 
persistent forms of AF are independent risk factors 
for late AF recurrence after PVI.
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